Dylan M. Marchione
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dylan M. Marchione has a total of 263 co-authors. Here are the top co-authors by number of shared publications:
- Aj S. Bottoms
Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts
29 shared publications - Alice S. Mims
The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
29 shared publications - Amir Tahmasb Fathi
Mass General Brigham Cancer Institute, Harvard Medical School, Boston, MA, United States
29 shared publications - Andrew Mark Brunner
Center for Leukemia, Massachusetts General Hospital, Boston, MA, USA
29 shared publications - Annette S. Kim
University of Michigan
29 shared publications - Areej El-Jawahri
Massachusetts General Hospital, Boston, MA
29 shared publications
Latest Publications
- Open Access
- 9 February 2026
- Published by Cold Spring Harbor Laboratory in Genes & Development
- Vol. 40 (9-10) , 650-665
The conserved N-terminal SANT1-binding domain (SBD) of EZH2 regulates PRC2 activity
Polycomb group proteins maintain gene expression patterns established during early development, with Polycomb repressive complex 2 (PRC2) methyltransferase being a key regulator of cell differentiation, identity, and plasticity. Consequently, extensive somatic mutations in PRC2, including gain or loss of function (GOF or LOF), are observed in human cancers. The regulation of chromatin structure by PRC2 is critically dependent on its enhancer of zeste homolog 2 (EZH2) subunit, which catalyzes the methylation of histone H3 lysine 27 (H3K27). Recent structural studies of PRC2 revealed extensive conformational changes in the noncatalytic EZH2 N-terminal SANT1-binding domain (SBD) during PRC2 activation, though the functional significance remains unclear. Here, we investigated how the SBD regulates PRC2 function. The domain is highly conserved in metazoans and dispensable for PRC2 assembly and chromatin localization yet is required for genome-wide histone H3K27 methylation. Furthermore, we show that an intact SBD is necessary for the proliferation of EZH2-addicted lymphomas, and its deletion in the presence of EZH2 GOF mutations inhibits cancer cell growth. These observations provide new insights into the regulation of PRC2 activity in normal development and malignancy.
- 9 February 2026
- Published by Cold Spring Harbor Laboratory in Genes & Development
- Vol. 40 (9-10) , 650-665
Open AccessThe conserved N-terminal SANT1-binding domain (SBD) of EZH2 regulates PRC2 activity
Polycomb group proteins maintain gene expression patterns established during early development, with Polycomb repressive complex 2 (PRC2) methyltransferase being a key regulator of cell differentiation, identity, and plasticity. Consequently, extensive somatic mutations in PRC2, including gain or loss of function (GOF or LOF), are observed in human cancers. The regulation of chromatin structure by PRC2 is critically dependent on its enhancer of zeste homolog 2 (EZH2) subunit, which catalyzes the methylation of histone H3 lysine 27 (H3K27). Recent structural studies of PRC2 revealed extensive conformational changes in the noncatalytic EZH2 N-terminal SANT1-binding domain (SBD) during PRC2 activation, though the functional significance remains unclear. Here, we investigated how the SBD regulates PRC2 function. The domain is highly conserved in metazoans and dispensable for PRC2 assembly and chromatin localization yet is required for genome-wide histone H3K27 methylation. Furthermore, we show that an intact SBD is necessary for the proliferation of EZH2-addicted lymphomas, and its deletion in the presence of EZH2 GOF mutations inhibits cancer cell growth. These observations provide new insights into the regulation of PRC2 activity in normal development and malignancy.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Supplemental Figure 2: Overall and progression-free survival for patients according to NPM1 mutational status
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Supplemental Figure 2: Overall and progression-free survival for patients according to NPM1 mutational status
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Marrow IDH1 VAF prior to Transplant and Maintenance
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Marrow IDH1 VAF prior to Transplant and Maintenance
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Supplemental Figure 1: Overall and progression-free survival for patients, according to whether the transplant followed first line or second line treatment.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Supplemental Figure 1: Overall and progression-free survival for patients, according to whether the transplant followed first line or second line treatment.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Representativeness of Study Participants
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Representativeness of Study Participants
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Supplemental Figure 2: Overall and progression-free survival for patients according to NPM1 mutational status
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Supplemental Figure 2: Overall and progression-free survival for patients according to NPM1 mutational status
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Marrow IDH1 VAF prior to Transplant and Maintenance
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Marrow IDH1 VAF prior to Transplant and Maintenance
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Marrow IDH1 VAF prior to Transplant and Maintenance
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Marrow IDH1 VAF prior to Transplant and Maintenance
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Representativeness of Study Participants
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Representativeness of Study Participants
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Supplemental Figure 1: Overall and progression-free survival for patients, according to whether the transplant followed first line or second line treatment.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Supplemental Figure 1: Overall and progression-free survival for patients, according to whether the transplant followed first line or second line treatment.